Advertisement

Topics

Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

08:30 EDT 23 Sep 2016 | Think Science Now
  • Transaction expected to close in the Third-Quarter 2016

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer’s pending acquisition of Medivation, Inc. (NASDAQ: MDVN).

Pfizer now expects to complete the acquisition in the Third-Quarter 2016. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding shares of Medivation common stock.

Language:
English
Contact:

For Pfizer:
Media:
Joan Campion, 212-733-2798
or
Investors:
Ryan Crowe, 212-733-8160

Ticker Slug:
Ticker:
PFE
Exchange:
NYSE
ISIN:
US7170811035
Ticker:
MDVN
Exchange:
NASDAQ

read more

Original Article: Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

NEXT ARTICLE

More From BioPortfolio on "Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...